

**AMENDMENTS TO THE CLAIMS:**

This listing of claims will replace all prior versions and listings of claims in the application:

**LISTING OF CLAIMS:**

1 - 27. (Cancelled).

28. (Previously Presented) Concentrated, stable solution, especially an injection solution or an infusion solution, characterized in that it contains beside water either (6S)-sodium-folate or (6S)-potassium-folate.

29. (Previously Presented) Solution according to claim 28, characterized in that it is prepared according to a process wherein amorphous (6S)-folinic acid is suspended in water, that is degassed and that is acceptable for the preparation of injection solutions or of infusion solutions, at room temperature under an inert gas atmosphere, then

an aqueous solution of sodium or potassium hydroxide, -hydrogencarbonate or -carbonate is added in portions during such a long time until a clear solution is formed having the respective desired pH value,

the obtained solution is subjected to a sterile filtration, and  
the obtained sterile solution is filled into vials or into ampoules under an inert gas atmosphere.

30. (Previously Presented) Solution according to claim 29, characterized in that the amorphous (6S)- folinic acid is prepared according to a process wherein is added to stirred water having a temperature from 2°C to 12°C simultaneously

- an aqueous solution having a temperature from 40°C to 50°C of (6S)-calcium-folate,  
and

- an aqueous solution of hydrochloric acid or of acetic acid

in such a way that in the obtained mixture during the addition of both of said solutions on one hand the temperature is kept at a value from 2°C to 12°C and on the other hand the pH value is kept at a value from 2.5 to 3.5,

the formed solid is isolated by means of filtration or centrifugation,

this solid is washed first with cold water and then with an aqueous organic solvent, and

the washed solid, that is amorphous (6S)-N(5)-formyl-5,6,7,8-tetrahydrofolic acid, is dried under reduced pressure and is obtained.

31. (Previously Presented) Solution according to claim 30, characterized in that the stirred water, to which said two solutions are added simultaneously, has a temperature from 6°C to 10°C.

32. (Previously Presented) Solution according to claim 30, characterized in that the aqueous solution of (6S)-calcium-folate has a concentration from 3.0 % by weight to 3.7 % by weight, preferably 3.5 % by weight.

33. (Currently Amended) ~~The process~~ Solution according to claim 30, characterized in that the aqueous solution of (6S)-calcium-folate has a temperature of 46°C.

34. (Previously Presented) Solution according to claim 30, characterized in that the aqueous solution of hydrochloric acid has room temperature and has a concentration from 10 % by weight to 20 % by weight, preferably 18 % by weight.

35. (Previously Presented) Solution according to claim 30, characterized in that in the obtained mixture during the simultaneous addition of both of said solutions the temperature is kept at a value from 6°C to 10°C.

36. (Previously Presented) Solution according to claim 30, characterized in that in the obtained mixture during the simultaneous addition of both of said solutions the pH value is kept at a value from 2.8 to 3.2.

37. (Previously Presented) Solution according to claim 30, characterized in that after the realized simultaneous addition of both of said solutions the obtained mixture is stirred for 1 additional hour at a temperature from 6°C to 10°C.

38. (Previously Presented) Solution according to claim 30, characterized in that the formed amorphous solid is washed after the washing with cold water with a 94:6 mixture (v/v) of ethanol and water.

39. (Previously Presented) Solution according to claim 28, characterized in that it contains from 2 % by weight to 15 % by weight, especially from 2 % by weight to 6 % by weight, preferably 5 % by weight, of (6S)-sodium-folate or (6S)-potassium-folate.

40. (Previously Presented) Solution according to claim 28, characterized in that it has a pH value in the range from 7.5 to 8.5, especially 7.9 to 8.1, preferably 8.0.

41. (Previously Presented) Solution according to claim 28, characterized in that it contains neither a stabilizer nor a complexing agent.

42. (Previously Presented) Solution according to claim 28, characterized in that it is filled into vials or into ampoules having in their interior an inert gas atmosphere, especially a nitrogen atmosphere.

43. (Previously Presented) Vials or ampoules, characterized in that there is filled into them a concentrated, stable solution according to claim 28.

44. (Previously Presented) Use of the solution according to claim 28 for the preparation of a medicament for rescues - rescue agent - after the treatment with high doses of methotrexate.

45. (Previously Presented) Use of the solution according to claim 28 for the preparation of a medicament which is combined with 5-fluorouracil.

46. (Previously Presented) Use of the solution according to claim 28 for the preparation of a medicament for the treatment of megaloblastic anemia and dihydro-pteridin reductase deficiency.